Therapy Areas: Infectious Diseases
US FDA Clears Precigen IND to Initiate Phase 1/1b Study for First-in-Class PRGN-3006 UltraCAR-T Therapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndrome
Login
Username:

Password: